Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE

Washington University boosted its holdings in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 33.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 280,802 shares of the company’s stock after purchasing an additional 70,121 shares during the quarter. Maze Therapeutics accounts for approximately 5.9% of Washington University’s investment portfolio, making the stock its 2nd largest holding. Washington University’s holdings in Maze Therapeutics were worth $11,634,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Vanguard Group Inc. boosted its position in Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Woodline Partners LP increased its holdings in Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after purchasing an additional 94,529 shares in the last quarter. Marshall Wace LLP raised its position in Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics in the third quarter valued at about $14,135,000.

Analyst Ratings Changes

MAZE has been the subject of several analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. HC Wainwright upped their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Wedbush lifted their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Finally, Truist Financial started coverage on shares of Maze Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $68.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $66.44.

Maze Therapeutics Trading Down 2.7%

Shares of NASDAQ:MAZE opened at $29.05 on Thursday. The firm has a market cap of $1.44 billion, a PE ratio of -8.99 and a beta of 5.14. The company has a fifty day simple moving average of $44.79 and a 200 day simple moving average of $37.94. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08.

Insider Buying and Selling

In other news, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Harold Bernstein sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 112,500 shares of company stock worth $5,132,812.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.